Research & Development
At the forefront of this field in Europe
In 2012, the PrenaTest® was the first blood test in all of Europe to employ this new, risk-free test method. Since then, we have continued to further develop it. Today, the test detects eight different chromosomal disorders and also identifies the gender of the fetus on request. Of course, we will also endeavor to remain at the forefront of this field well into the future. Many innovative developments are already underway.
| September 2018 | Market launch of the NIPD-RhD – Non-invasive prenatal RhD genotyping from maternal blood |
| Aug 2017 | 5 years PrenaTest® – More than 80,000 successfully performed PrenaTest® analyzes in Germany with blood samples of pregnant women from 50 countries in Europe, the Middle East and Asia |
| April 2017 | Start of research and development of a molecular genetic assay for the early detection of pre-eclampsia (research alliance with the Charité Berlin) |
| Dez 2016 | CE approval for qPCR-based NIPT solution for the detection of fetal trisomy 21 (qNIPT) |
| Nov 2016 | Prospective clinical follow-up study with over 2,200 patients: Confirmation of the excellent test quality of the PrenaTest® |
| Mai 2016 | PrenaTest® now also analyzed in Munich: second German technology transfer to the Aerzteverbund praena bayern completed |
| März 2016 | PrenaTest® now also analyzed in Cologne: First German technology transfer to the lab Dr. med. Wisplinghoff in Cologne completed |
| Juli 2015 | PrenaTest® now also analyzed in Switzerland: Technology Transfer to the Laboratory Medical Center Risch in Bern |
| Mai 2015 | PrenaTest® now also for the determination of the 22q11.2 microdeletion |
| Dez 2014 | Start of development of a qPCR-based NIPT assay (qNIPT) with the aim of further reducing the test price and waiting time to the test result |
| Sept 2014 | Start of the development of an innovative NIPT data analysis system (PrenaBoxx®). |
| Jun 2014 | PrenaTest® now also determines sex chromosomal aneuploidy (Turner, Triple X, Klinefelter and XYY syndrome) |
| Feb 2014 | PrenaTest® now also applicable to twin pregnancies |
| Okt 2013 | Reduction of the waiting time to the test result to one week by introducing the PrenaTest®express |
| Juli 2013 | PrenaTest® now ready for use after the ninth week of pregnancy has been completed (week 9+0 since LMP) Introduction of the proprietary QuantYfeX® assay to measure the fetal fraction upon sample receipt |
| Feb 2013 | PrenaTest® now also determines fetal trisomies 13 and 18 |
| Aug 2012 | Market launch of the PrenaTest® – Europe’s first NIPT – for the determination of fetal trisomy 21 from gestational week 12+0 since LMP |
| Juni 2012 | CE Marking of proprietary bioinformatic analysis software (PrenaTest® DAP.plus) according to European IVD Directive |
| Sept 2011 | License agreement with Sequenom Inc. (USA) for the acquisition of rights of use of essential patents as a legal requirement for the conduct of non-invasive prenatal tests (NIPT) in Germany |
| April 2010 | Start of operative work on research and development of innovative and clinically validated non-invasive genetic tests |
